- 中文名稱
Envafolimab 生物類似藥, PD-L1 單克隆抗體
- 英文名字
- Envafolimab Biosimilar, PD-L1 Monoclonal Antibody
- 供應商
- Promab
- 產品貨號
- PMB-B00056
- 產品報價
- ￥詢價/1mg/5mg/20mg
- 產品說明書
- 點擊查看
- 購買方式
- 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868
- 產品新聞
- 背景資料
- What is envafolimab biosimilar research grade? Envafolimab is a humanized nanobody (VHH-hIgG1 Fc fusion protein) directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Envafolimab biosimilar uses the same protein sequences as the therapeutic antibody envafolimab.nnPD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Envafolimab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
- 應用類型
- Flow cytometry, animal model study
- 免疫原
- Human PD-L1
- 來源宿主
- CHO cells
- 反應性
- Human
- 保存建議
- Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
- 其他
- KN035, KN035-Fc, VHH-Fc Fusion Protein, PD-L1 Nanobody
- 注意
-
該頁面的中文產品信息的翻譯，僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前，請瀏覽說明書確認。
-
